Therefore, it will be necessary to understand the molecular regulations of Nrf2/TrxR and identify the individualized status of Nrf2/TrxR expression in imatinib-resistant CML. Here, NFE2L2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.